Investigational drug for breast cancer patients with brain metastases

Trial ID:
IRB-25-8588
Tresa McGranahan, MD PhD

Inclusion Criteria

Patients must:

  • Be at least 18 years old
    Have histologically confirmed HER2- metastatic brain cancer and at least one measurable intracranial lesion
    Have 0-3 prior lines of chemotherapy in advanced or metastatic setting

Exclusion Criteria

Patients must not:

  • Have leptomeningeal metastasis confirmed by MRI and/or cerebrospinal fluid cytology
    Have any intracranial lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions)
    Have had evidence of intracranial hemorrhage within 12 months before study treatment

Additional Info

All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines/Green Hospital in La Jolla and Scripps Prebys Cancer Center/Mercy Hospital in Hillcrest.

For more details search for the NCT #, NCT06764940, on the ClinicalTrials.gov website (https://clinicaltrials.gov).

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org